Best Deals Of The Week: ECOVACS, Apple, Cotton On, The Oodie
If cleaning feels like a chore, let a robot do the work for you. We've spotted a whopping 54 per cent off the ECOVACS Deebot T30 Omni Robot Vacuum Cleaner with Wiping Function that's been praised by five-star rating shopper as 'intelligent and efficient'.
If you're after something more budget-friendly, the 'miracle' ECOVACS DEEBOT N20 Plus Robot Vacuum Cleaner and Mop is on 47 per cent off, down to a mere $499. Rave reviewers claim its 'worth every cent' – run, don't walk!
Thinking about grabbing a new pair of earbuds? Apple's 'superior quality' audio is on sale at Amazon for an unmissable price.
You can either grab the Apple AirPods 4 for $188 (down from $219) or the Apple AirPods Pro (2nd Gen) with MagSafe Case (USBâ€'C) for $347 (down from $399).
Our favourites over at Cotton On are slashing a mega 50 per cent off the cosy edit - think knitwear, jackets, jeans, sweaters and so much more.
You can also head on over to The Oodie and pick yourself up an 'ultra cosy and comfy' hooded blanket. The Aussie-fave is offering 30 per cent off sitewide – this is your chance to score a big discount!
Happy shopping!
In this article
Please note: price are correct and products in stock at time of publishing. We'll do our best to keep this story updated, but be aware products move fast during sales events.
EDITOR'S PICKS: BEST DEALS OF THE WEEK
Cotton On
50 per cent off the cosy edit
Amazon Australia
Esmi
Shark
Myer
Ninja
City Chic
MCM House
30 per cent off all sofas, modulars and armchairs for a limited-time only
DB Cosmetics
Up to 70 per cent off sale
The Oodie
Shop the clearance sale – nothing over $49
30 per cent off sitewide
Unreal Skin
Clarks
40 per cent off everything
Bae the Label
Extra 20 per cent off sale
Country Road
Up to 50 per cent off selected styles
Dyson
eBay
Unwritten Hair
Get the best-selling Hydration Repair Trio, plus a free $89.95 Wooden Cushion Brush
Emamaco
Shop the epic outlet sale
SmilePro
Smilie
Up to 50 per cent off sale
$100 off Smilie Boost Teeth Whitening Kit, $119 (down from $219)
Ergoflex
Yinahla
15 per cent off mattresses
Sleep Firm
15 per cent off mattresses
Emma Sleep
Up to 40 per cent off sale
40 per cent off the Emma Luxe Pro Mattress
25 per cent off the Emma Comfort Protect Mattress
10 per cent off the Emma Metal Bed
BEST TRAVEL DEALS
Monos
$150 off luggage sets
American Tourister
Up to 50 per cent off sale
July
Bundle and save up to $125 off
Samsonite
40 per cent off selected styles
Strand
Up to 40 per cent off sale
BEST HOME DEALS
Sheridan
30 per cent off bed linen
Sheridan Outlet
Up to 50 per cent off sale – members only
Bed, Bath N' Table
Nespresso
25 per cent off selected Original coffee machines
25 per cent off selected Vertuo coffee machines
Sleeping Duck
Save up to $200 off bundles
Temple & Webster
Up to 40 per cent off the warehouse sale
Pillow Talk
Our Place
James Lane
20-50 per cent off when you buy two or more items
Maison Balzac
Shop the final sale
Canningvale
Up to 90 per cent off sale
KitchenAid
Up to 15 per cent off
Sheet Society
20 per cent off selected styles
BEST TECH DEALS
Samsung
The Good Guys
Lenovo
Up to 40 per cent off sale
Vodafone
Get 60GB for just $43/mth
Bose
Shop the winter sale
JBL
Up to 50 per cent off sale
Sonos
BEST FASHION DEALS
Witchery
Hype DC
Up to 40 per cent off selected styles
CAMILLA
Extra 20 per cent off sale
The Athlete's Foot
Up to 40 per cent off sale
Platypus Shoes
Up to 40 per cent off sale
Dr Martens
Shop the Afterpay Day sale
Van Heusen
40 per cent off sitewide
Get three shirts for $119
Superdry
30-50 per cent off jackets
Net-A-Porter
Up to 60 per cent off sale
Novo Shoes
25 per cent off almost everything
Calvin Klein
Viktoria & Woods
Extra 30 per cent off sale
Under Armour
Spend and save up to 30 per cent off for Father's Day
Lorna Jane
20 per cent off selected styles
Adidas
Shop the outlet sale
Nike
Up to 40 per cent off sale
Tommy Hilfiger
30 per cent off menswear and kidswear
Gorman
20-50 per cent off sale
Princess Highway
20-60 per cent off sale
Dangerfield
20-60 per cent off sale
Coach Outlet
40 per cent off sitewide
Oroton
40 per cent off sale, plus an extra 20 per cent off selected styles
Christopher Esber
Shop the end of season sale
UGG Express
Up to 80 per cent off sale
Elka Collective
Shop the end of season sale
Stylerunner
Extra 30 per cent off selected sale
Betts
30 per cent off sitewide
Le Specs
BEST HEALTH AND BEAUTY DEALS
the breakout hack
Bundle and save up to 30 per cent off your order
iHerb
20 per cent off sports
20 per cent off healthy habits
Priceline
Your Reformer
SkinCeuticals
20 per cent off routine sets
MAC Cosmetics
20 per cent off sitewide
Sephora
Up to 50 per cent off sale
LELO
Up to 40 per cent off sale
Lovehoney
Up to 70 per cent off sale
Free gifts when you spend over $140
Shaver Shop
Up to 80 per cent off sale
Laser Clinics Australia
50 per cent off selected hair removal
40 per cent off AquaFacial Treatments
Wild Secrets
Up to 70 per cent off sale
Sign up to our weekly shopping newsletter to get all the best deals, shopping tips and guides delivered straight to your inbox.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
5 hours ago
- News.com.au
Biocurious: Clinical trial readouts show road to approval can be as exciting as the destination
In the medical device sector, sometimes trial news can excite investors more than the approval endgame At the application stage, devices have a much higher chance of being approved than drugs Investors can expect news from several companies with pivotal or late-stage trials For a drug or device maker, there's no prouder moment than when a health regulator – especially the US Food & Drug Administration (FDA) – approves their product to be unleashed on unsuspecting patients. It's like watching your kid graduate – and you can even tolerate the long-winded speeches. But don't confuse this coming-of-age moment with being the ultimate share price catalyst. For investors, the 'ker-ching' can be much earlier, such as with trial progress or even the FDA granting permission to begin a study. For instance, PainChek (ASX:PCK) shares had a nice run last October, after a positive validation study that supported the pain measurement app maker's US approval application. In late June Blinklab (ASX:BB1) shares soared after the autism test developer won ethics approval for a 1000-patient US trial. In the case of devices, FDA device approval tends to be less of a dramatic moment than for a drug go-ahead, because the chances of success are much higher. Most applicants avail of the 510(k) route, which means that a device only needs to be substantially equivalent to a legal equivalent. According to the contract research organisation Bioaccess, the FDA processes around 10,000 510(k) applications annually, with an approval rate of around 90%. Review times are also shorter: 120 days compared with 420 days for the de novo (new device) route. Here are some device (or quasi device) plays with advanced trials – typically- pivotal ones – that could move the share price dial. Emvision runs with Emu trial EMvision Medical Devices (ASX:EMV) in enrolling up to 300 suspected stroke victims in a pivotal trial of its stroke detection device Emu, across six local and US sites. Emu is a portable bedside scanning unit that's much lighter than a conventional computed tomography (CT) unit. The company is also developing an even small version, First Responder. As its name suggests, this one's for ambulance use. The trial sites are all high calibre research centres handling high stroke volumes. The stroke patients will receive the standard of care and an Emu scan. Given the device is a trail blazer, Emvision is girding for approval under the de novo route. After that, the company hopes the agency will approve First Responder approval under the 510(k) channel. Emu/First Responder will determine whether a stroke is a blockage (ischaemic)or a bleed (hemorrhagic). This will decide the type of treatment and it's crucial to get the diagnosis right. The company expects a six-to-12-month recruitment period. Micro-X also is on strike with strokes Meanwhile, x-ray imaging house Micro-X (ASX:MX1) plans to launch trails of its portable stroke unit, Head CT, across three local hospitals in the current half. The trials will entail suspected stroke victims being subject to standard CT imaging, then overlaid with the Micro-X scan that deploys a more effective 'cold cathode' method. Aiming for 'several hundred' scans, the studies only need to prove that the Micro-X tech is just as good as the conventional ones, Funded by $8 million from the Australian Stroke Alliance, the study supports a proposed 510(k) application next year, in view of a US launch in 2027. The company expects the trials to run for nine months. Micro-X had multiple applications for its tech, bomb and baggage screening. As part of a 'strategy re-set' the company is focused on medical applications. Micro-X has commercialised two mobile digital radiology devices: the first-generation Nano and a sturdier iteration called Rover. Heart patients move like Jagger In the past, heart patients too old or too sick for surgical aortic valve replacement – or open-heart surgery – in effect were given a death sentence. Transcatheter Aortic Valve Replacement (TAVR) procedures enable malfunctioning valves to be replaced in a non-invasive, 20-minute procedure. TAVR recipients include Arnold Schwarzenegger and Mick Jagger – and they're still rockin'. TAVR also applies to replacing artificial valves that have an effective operating life of five years or so. Anteris Technologies (ASX:AVR) is on track to commence a pivotal trial of its Duravr device in the current quarter, pending FDA approval. The company says it's qualified 79 sites globally for the trial, which will enroll patients with a 'broad array of risk profiles'. The trial will be designed to provide the 'primary clinical evidence' for the FDA to mull premarket approval. In parallel, Anteris is pursuing European clearance. More than Imagion-ation Shares also can pop on the strength of trial approval alone. In the drug/device sphere, Imagion Biosystems (ASX:IBX) awaits clearance to carry out a phase II study of its cancer imaging agent, Magsense for Her-2 positive beast cancers. For use with magnetic resonance imaging (MRI), Magsense improves cancer detection by adding 'molecular specificity'. In lay terms, this avoids painful, error-prone biopsies. This month, Imagion formed an alliance with Michigan's Wayne State University School of Medicine. In part, the institution's MRI gurus will help to devise an optimal dose to be used in the study. Trip the light fantastic Invion (ASX:IVX) highlights how the trial journey, rather than the destination can evoke investor excitement. Invion is advancing photodynamic therapy (PDT) for tumor types including non-melanoma skin cancers and ano-genital cancers. Someone has to do it. The idea is that light-activated photosensitisers leave the healthy tissue unharmed, but zap the diseased stuff. Thus, PTD is a promising non-toxic, non-invasive alternative to chemotherapy, radiation or surgery. Invion shares early last December rocketed more than 300% after the company said it had enrolled its first patient in its Queensland based phase I/II skin cancer trial. The adaptive study now is poised to enter is second stage. The next Sirtex? OncoSil Medical (ASX:OSL) is equated with a less developed version of the targeted liver cancer radiation treatment house Sirtex, acquired for $1.9 billion in 2018 by Chinese interests. Relative commercial immaturity aside, Oncosil targets the difficult pancreatic cancer. Oncosil is trialling its eponymous targeted treatment with the standard-of-care chemo, Folfirinix. The study, TRIPP-FFX, has completed recruitment and investors should expect data in early 2026. The study pertains to patients with locally advanced pancreatic cancer. The trial has recruited 'at least' 88 patients across 15 local and European hospitals. So - there you have it. While bonanza share gains are never guaranteed, investors know where to look for surprise pit stops along the circuitous approval journey.
News.com.au
13 hours ago
- News.com.au
Woolies slashes prices of 100-plus products from Wednesday
Woolworths has slashed prices on nearly 700 everyday products, with the cost of more than 100 items – including pantry staples like pasta sauce and olive oil spray – dropping this week. Woolworths has expanded their Lower Shelf Price initiative, locking in lower prices across hundreds of everyday essentials. More than 100 items will become cheaper from Wednesday, August 20, with prices on these products set to drop about 14 per cent on average, according to Woolworths. 'Across the total basket of the new 100-plus products added to Lower Shelf Price this month, customers could save up to $110,' Woolworths said in a statement. Essentials to be slashed on Wednesday include Sacla pasta sauce 420g, Woolworths extra virgin olive oil spray, Woolworths jasmine rice 5kg and Indomie mi goreng noodle cups. Customers can view all the products available on Lower Shelf Price on the Woolworths website from Wednesday. 'We know that providing consistent, reliable value to our customers is more important than ever,' Woolworths chief executive Amanda Bardwell said. 'Since launch we have seen the lower shelf prices resonate with our customers and we're seeing families embrace the savings on key staples such as bread, yoghurt, cheese and baby wipes. 'Our customers are telling us that these dependable prices are helping them plan and manage their weekly shop with more confidence. 'This is not about temporary specials but about long-term shelf price certainty on the products that matter most for families'.
News.com.au
19 hours ago
- News.com.au
Tesla goes rogue with new Grok AI
Tesla is no stranger to bold, unconventional ideas, but its Grok AI 'Unhinged Mode' is pushing things further than ever. The feature has been making headlines for its savage, unfiltered comebacks that fit squarely within Elon Musk's brand of edgy, meme-ready tech. Unlike other AI assistants that play it safe, Grok's unhinged personality has shocked users with its profanity-laced humour and aggressive banter. TikTok creator Kyle Krueger recently tested the mode and was stunned by the responses. When he asked if it was in 'unhinged mode,' Grok fired back: 'Oh, you f****** bet your sweet a** I'm in unhinged mode, you glorious chaos gremlin,' it said. 'I'm Ara, you're unfiltered bat**** crazy AI sidekick.' @kylekruegerr my tesla's new AI just LOST it 😂 wait till the end #tech #gadget #tesla #grok #elon ♬ original sound - Kyle Krueger When pressed about Tesla haters, the AI went even further, unloading a tirade of expletives and insults 'Those whiny limp d*** b****** can choke on a bag of rusty spark plugs,' the AI bot said. 'They are just jealous their gas guzzling s*** boxes can't touch Elon's electric w*** d****.' And this isn't the first time Grok's AI bot has had a brush with controversy. Earlier this year, the AI system made headlines after generating antisemitic remarks and praise for Hitler following the release of Grok 4. Those incidents triggered regulatory scrutiny in Europe and a temporary ban in Turkey. While the Grok rants can be entertaining, there are concerns about how the use of profanity and an absurd personality in an in-car AI might create problems. 'You know, this feels wrong. Electric cars were made with the purpose to help with the environment and they implemented an AI hat is not good for the environment? weird.' one user on commented. 'How is this allowed,' another said. Despite the backlash, Tesla insists Grok is 'designed to deliver accurate and insightful responses across a wide range of topics.' In North America, Grok is available on specific Tesla models, including the Model S, Model 3, Model X, Model Y, and Cybertruck. To use Grok, Tesla vehicles in the US must be equipped with an AMD processor, must run software version 2025.26, and must have Wi-Fi connectivity. With Tesla's board weighing an investment in xAI and Musk confirming plans to integrate Grok into Optimus humanoid robots, the chatbot is quickly becoming central to Musk's long-term strategy. Whether you see it as a gimmick or a waste of tech, Grok's unhinged represents a pattern of intentionally chaotic innovations developed by Elon Musk. Tesla Australia has not yet confirmed whether Grok AI will be available in its vehicles here. However, if there are plans to introduce it, there may be restrictions that differ from those in the US. These variations could affect what Australians can anticipate compared to the features currently accessible in the US.
